Bahl & Gaynor’s Innospec IOSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-27,306
Closed -$2.11M 332
2025
Q3
$2.11M Buy
27,306
+731
+3% +$61K 0.01% 201
2025
Q2
$2.23M Sell
26,575
-4,368
-14% -$382K 0.01% 200
2025
Q1
$2.93M Sell
30,943
-5,013
-14% -$530K 0.01% 189
2024
Q4
$3.96M Sell
35,956
-1,944
-5% -$222K 0.02% 179
2024
Q3
$4.29M Buy
37,900
+282
+0.7% +$32.8K 0.02% 182
2024
Q2
$4.65M Buy
37,618
+1,457
+4% +$182K 0.03% 174
2024
Q1
$4.66M Buy
36,161
+160
+0.4% +$19.4K 0.03% 173
2023
Q4
$4.44M Buy
36,001
+1,177
+3% +$125K 0.03% 169
2023
Q3
$3.56M Buy
34,824
+18,407
+112% +$1.92M 0.02% 173
2023
Q2
$1.65M Buy
+16,417
New +$1.64M 0.01% 221

Other funds holding IOSP

Bahl & Gaynor's IOSP Position: Q4 2025 in Review

Bahl & Gaynor sold out of Innospec (IOSP) in Q4 2025, closing a stake of 27,306 shares — an estimated $2.11M sold.

Bahl & Gaynor first reported a position in IOSP in Q2 2023 and held it in 10 quarters. The position peaked at $4.66M in Q1 2024. 260 funds tracked by Wall St. Rank hold IOSP as of Q4 2025.

  • Bahl & Gaynor reported no remaining Innospec position as of Q4 2025 after selling out during the quarter.
  • Bahl & Gaynor sold 27,306 Innospec shares in Q4 2025, an estimated $2.11M.
  • Bahl & Gaynor first reported a position in Innospec in Q2 2023 and held it in 10 quarters.
  • Bahl & Gaynor's Innospec position peaked at $4.66M in Q1 2024.
  • 260 funds tracked by Wall St. Rank held Innospec as of Q4 2025.

Based on Bahl & Gaynor's 13F filing for Q4 2025, filed 12 Feb 2026.